Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Atypical presentation of multiple sclerosis.
Remyelination Therapy in Multiple Sclerosis.
The cerebellar channelopathy of multiple sclerosis.
Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.
The common marmoset as an indispensable animal model for immunotherapy development in multiple sclerosis.
Celastrol Ameliorates EAE Induction by Suppressing Pathogenic T Cell Responses in the Peripheral and Central Nervous Systems.
Epigenetic regulation of polyomavirus JC involves acetylation of specific lysine residues in NF-κB p65.
Predictors of chronic cerebrospinal venous insufficiency procedure use among older people with multiple sclerosis: a national case-control study.
Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO.
Activation Status of Human Microglia Is Dependent on Lesion Formation Stage and Remyelination in Multiple Sclerosis.
Neuroprotective arylpiperazine dopaminergic/serotonergic ligands suppress experimental autoimmune encephalomyelitis in rats.
Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases.
Peroxisome proliferator activated receptor-γ agonists protect oligodendrocyte progenitors against tumor necrosis factor-alpha-induced damage: Effects on mitochondrial functions and differentiation.
Therapeutic Plasma Exchange in Glucocorticosteroid-Unresponsive Patients With Clinically Isolated Syndrome.
Impairment of JCV-specific T-cell response by corticotherapy: Effect on PML-IRIS management?
Disclosing a misdiagnosis of multiple sclerosis: do no harm?
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.
A case of relapsing-remitting tumour-like inflammation of the central nervous system.
Physical activity and pediatric multiple sclerosis: Developing a research agenda.
["Time is brain" in relapsing remitting multiple sclerosis : Current treatment concepts in immunotherapy].
Improved Lesion Detection by Using Axial T2-Weighted MRI with Full Spinal Cord Coverage in Multiple Sclerosis.
Microglia: A Unique Versatile Cell in the Central Nervous System.
Physiological Role of K(+) Channels in the Regulation of T Cell Function.
Axon damage in central nervous system and peripheral nervous system inflammatory demyelinating diseases: common and divergent pathways of dysfunction and tissue damage.
Disease activity return after natalizumab cessation in multiple sclerosis.
Pages
« first
‹ previous
…
601
602
603
604
605
606
607
608
609
…
next ›
last »